Posted by Michael Wonder on 27 Apr 2018
ICER releases draft condition update report on treatments for plaque psoriasis
27 April 2018 - Public comment period now open until 25 May; requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review (ICER) today released a draft evidence report assessing the comparative clinical effectiveness and value of treatments for moderate-to-severe plaque psoriasis. The review will be open to public comment until May 25, 2018. Findings contained in this report are preliminary and subject to change based on additional stakeholder input and further analysis of data.
ICER previously reviewed treatments for plaque psoriasis in 2016. In addition to incorporating emerging clinical data for previously reviewed therapies, this condition update report includes new analyses of guselkumab (Tremfya, Johnson & Johnson), tildrakizumab (Ilumya, Sun Pharma/Merck), certolizumab pegol (Cimzia, UCB), and risankizumab (AbbVie). Certolizumab pegol is currently approved for use in several other indications, including rheumatoid arthritis, and an approval decision for its plaque psoriasis indication is expected in May 2018. Risankizumab was added to the scope of the review based on feedback received during conversations with manufacturers and clinical experts. The drug has not yet been filed for FDA review.
